Copanlisib + rituximab versus rituximab + placebo in patients with relapsed follicular (FL) or marginal zone lymphoma (MZL): Subset analysis from the phase III CHRONOS-3 trial.

Matthew J. Matasar,Marcelo Capra,Muhit Ozcan,Fangfang Lv,Wei Li,Eduardo Yáñez,Katya Sapunarova,Tongyu Lin,Jie Jin,Wojciech Jurczak,Aryan Hamed,Ming-Chung Wang,Lidia Mongay Soler,Anjun Cao,Charles Phelps,Barrett H. Childs,Yuankai Shi,Pier Luigi Zinzani

Copanlisib + rituximab versus rituximab + placebo in patients with relapsed follicular (FL) or marginal zone lymphoma (MZL): Subset analysis from the phase III CHRONOS-3 trial.

2021

Matthew J. Matasar
Marcelo Capra
Muhit Ozcan
Fangfang Lv
Wei Li
Eduardo Yáñez
Katya Sapunarova
Tongyu Lin
Jie Jin
Wojciech Jurczak
Aryan Hamed
Ming-Chung Wang
Lidia Mongay Soler
Anjun Cao
Charles Phelps
Barrett H. Childs
Yuankai Shi
Pier Luigi Zinzani

7510Background: Rituximab (R) monotherapy is an approved treatment for patients (pts) with relapsed indolent NHL (iNHL) who have a prolonged progression-free and treatment-free interval after last ...

Keywords:

marginal zone lymphoma
Placebo
Internal medicine
Copanlisib
Medicine
Gastroenterology
Subset Analysis
in patient
Follicular phase
Rituximab

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations